Fecal microbiota transplantation for IBD will need to be adaptive and individualized moving forward, according to the American Gastroenterological Association.
Here are the key details to know:
1. Data is sparse on FMT's efficacy and safety with issues beyond C.diff patients.
2. However, FMT may be a promising treatment for ulcerative colitis.
3. For treating IBD patients, the type of bacteria needed for each patient seems to be different, creating the need to multiple doses at different intervals.
4. An article in Gastroenterology and Hepatology detailed the possibility of a monolithic superstool to treat heterogeneous patients across a range of complex diseases.